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NATURAL ANTIMICROBIAL PEPTIDES: A 
PALETTE OF EXTRAORDINARY COLORS
Virtually all multicellular organisms must 
ward off pathogenic microbes in order to 
survive and thrive on this planet. To accom-
plish this, most metazoans rely on gene-
encoded antimicrobial peptides (AMPs) 
as an essential part of their innate immune 
system. The role played by AMPs – and by 
the other umoral and cellular components 
of innate immunity – is particularly crucial 
in those organisms (the vast majority) that 
have not developed the more sophisticated 
adaptive immune system. Even in higher 
vertebrates as humans, AMPs like defensins 
and cathelicidins (e.g., LL-37) do not only 
have direct microbicidal activity, but they 
also serve as signals which initiate, mobi-
lize, and amplify adaptive immune host 
defenses, thus functioning as immunomod-
ulatory and immunostimulatory elements 
(Giuliani and Rinaldi, 2010).
Despite a bewildering variety in their 
primary sequences, AMPs generally share 
a cationic character, a length that usu-
ally does not exceeds 50 residues (a large 
proportion of which are generally hydro-
phobic), and a globally amphipathic fold, 
with clearly distinguishable hydrophilic 
and hydrophobic faces. These structural 
features reflect their mode of action, which 
is primarily directed to the interaction 
with and damage of the pathogen cell’s 
plasma membrane, although the evidence 
that many AMPs may hit other targets is 
rapidly increasing. These evolutionarily 
conserved molecules display a broad spec-
trum antimicrobial activity against bacte-
ria, fungi, protozoans, and even enveloped 
viruses. AMPs represent key components 
especially at epithelial surfaces, where the 
initial contact with pathogens takes place, 
thus being deployed at the very front line 
of the defense system, where rapid action is 
required before the more slowly respond-
ing adaptive immune system (if any) can 
be brought into action.
With the prospects of an ever-increas-
ing bacterial resistance to conventional 
antibiotics looming at the horizon, much 
attention has been devoted to AMPs as 
a potential source of new anti-infective 
drugs (Mangoni, 2011; Yeung et al., 2011). 
However, despite intense research aimed at 
spotting possible ways for harnessing the 
therapeutic potential of these intriguing 
natural compounds, little practical outcome 
has been generated as yet. Multiple hurdles 
on this way exist, indeed, related to the fact 
that naturally occurring AMPs present seri-
ous drawbacks that limit their development 
into clinically applicable antibiotics. These 
include (but are not limited to) high costs of 
manufacture, susceptibility to protease deg-
radation, reduced activity in the presence of 
salts as those present in serum. In addition, 
given the recognized immunomodulatory 
and immunostimulatory effect of several 
AMPs – that is some cases is so evident 
that the term Host Defense Peptides has 
been proposed as more indicative of the 
real role played by these molecules in vivo – 
using AMPs systemically to treat infections 
should necessarily suppose an advanced 
knowledge of (and possibility to control) 
the possible responses these peptides can 
trigger. Furthermore, as mentioned before, 
AMPs have been crafted by evolution to 
be part of the network of interacting and 
self-reinforcing components of the innate 
immune systems, thus expecting that they 
could stand alone as the new “magic bullet” 
against resistant microbes would be simply 
overoptimistic.
Given the inherent limitations of 
naturally occurring AMPs that have so 
far prevented their transformation into 
therapeutics, two general approaches have 
emerged to overcome this major obstacle, 
i.e., the modification of existing peptide 
sequences or the de novo synthesis of pep-
tides, and the development of synthetic 
molecules that mimic the properties and 
activities of AMPs (Giuliani et al., 2008; 
Brogden and Brogden, 2011; Fjell et al., 
2011; Giuliani and Rinaldi, 2011). Here, a 
few recent, significant examples pertaining 
to these research avenues will be highlighted.
DESIGNED PEPTIDE ANTIBIOTICS: 
RATIONALLY BANKING ON NATURE’S 
WORK
Several computational approaches have 
been proposed for the design of promis-
ing novel peptide antibiotics based on our 
current understanding of structure–activ-
ity relationships of the naturally occurring 
AMPs. One of the most interesting of such 
directions was reported by the group led 
by Davor Juretic´ at the University of Split, 
Croatia. By inspecting a self-assembled data-
base of natural AMPs where primary and 
secondary structures have been linked to the 
peptides’ antimicrobial activity and selectiv-
ity (i.e., the ability to discriminate bacterial 
versus host cells as targets), these research-
ers have extracted selected physicochemical 
peptide properties then used to construct 
a “AMP-Designer” algorithm (Juretic´ et al., 
2009). A peptide (23 residues, glycine-rich) 
suggested by the algorithm, was synthesized 
and its activity and selectivity tested. This 
peptide, adepantin 1 (from “Automatically 
DEsigned Peptide ANTIbiotic Number 1”), 
is less than 50% identical to any other AMP, 
and displayed a potent antibacterial activity 
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units for multimeric peptides – as well as 
greater stability to peptidases and proteases, 
possibly due to the steric hindrance of the 
branching core that would limit the cleavage 
rates of plasma peptidases, thus increasing 
the  peptides’ pharmacokinetics properties 
(Giuliani and Rinaldi, 2011).
Researchers at the University of Zurich 
and Polyphor Ltd.1 have used a different 
approach to come out with a Pseudomonas 
specific antibiotic with a novel mode of 
action. The lead, termed POL7080, was 
derived from the so-called PEM (protein 
epitope mimetic) technology platform, 
which takes advantage of the fact that 
molecular recognition involving proteins is 
often mediated by surface-exposed second-
ary structure motifs such as β-hairpins and 
α-helices (Obrecht et al., 2012). Following 
this path, researchers have developed 
epitope mimetics of protegrin I – an AMP 
lipopolysaccharide (LPS) in vitro (Bruschi 
et al., 2010). More recently, a novel AMP with 
a dimeric dendrimer scaffold, SB056 (Figure 
1A), was synthesized and showed high activ-
ity against Gram-negative bacteria and some 
limited activity against Gram-positive bac-
teria (Scorciapino et al., 2012). Its potency 
against Gram-negative strains was compara-
ble (on a molar basis) to that of colistin and 
polymyxin B, with an even broader spectrum 
of activity than numerous other reference 
compounds. Biophysical characterization 
through circular dichroism, NMR, molecular 
dynamics simulation, and membrane affin-
ity assayed through lipid monolayer surface 
pressure experiments, revealed that the pep-
tide is membrane-active, and tends to folds 
into a β-type conformation in a lipid envi-
ronment (Scorciapino et al., 2012). In gen-
eral, dendrimeric peptides display increased 
activity compared to their monomeric coun-
terparts – a fact probably attributable to 
the higher local concentration of bioactive 
against Escherichia coli coupled to a signifi-
cantly greater selectivity for bacterial cells 
than the best AMP present in the reference 
database (Juretic´ et al., 2009).
Multimeric peptides have proved to be 
another intriguing variation on the AMPs 
theme. Recently, several examples of pep-
tide dendrimers endowed with antimicrobial 
properties were reported. These molecules 
were designed following the so-called 
multiple antigenic peptide (MAP) system, 
introduced many years ago, where multiple 
peptide sequences can be added using stand-
ard solid phase chemistry to a inner core of 
radially branched lysine residues. Starting 
from a linear AMP sequence originally iden-
tified by selecting a random phage library 
against whole E. coli cells, several cycles of 
rational modification and optimization led 
to the tetra-branched peptide known as 
SB041, found to be especially active against 
Gram-negative strains and able to strongly 
bind E. coli and Pseudomonas aeruginosa 
Figure 1 | examples of designed antimicrobial peptides and mimics. (A) The 
dendrimeric peptide SB056. 8-Aoc is 8-aminooctanoic acid, which is amidated in 
the peptide construct; (B) antimicrobial oligourea; (C) arylamide compounds; (D) 
structures of an α-peptide and a corresponding AApeptide, and α-AApeptide 
building blocks (m1 and m2) used for the preparation of antimicrobial 
α-AApeptides; (e) lipo-γ-AApeptide. See text for more details and original studies.
1www.polyphor.com
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acids, designed on the principle of glob-
ally  amphipathic structures as drivers for 
membrane-active antimicrobial compounds 
(Figure 1D). “Coupled with straightforward 
solid phase synthesis, virtually limitless 
structural possibilities, low cost of produc-
tion, simple tunability and programmabil-
ity, and resistance to protease hydrolysis, 
α-AApeptides may lead to a new class of 
antimicrobial peptidomimetics,” remarked 
authors (Padhee et al., 2011). In their hands, 
one of the synthesized oligomers displayed 
minimal inhibitory concentration (MIC) val-
ues – defined as the lowest inhibitor concen-
tration that completely inhibits the growth of 
microbes during a 24 h incubation period at 
37°C – as low as 2.1 μg/ml against the Gram-
negative E. coli and 0.9 μg/ml against the 
Gram-positive Bacillus subtilis, respectively, 
while being non-hemolytic (Padhee et al., 
2011). These levels of activities are equal to or 
better than those of most natural AMPs and 
peptidomimetics reported so far. The same 
group, led by Jianfeng Cai at the University 
of South Florida in Tampa, FL, USA, lately 
reported the design and synthesis of lipidated 
γ-AApeptides (Figure 1E) as antimicrobial 
agents (Niu et al., 2012). According to the 
authors, the introduction of an unsaturated 
lipid chain significantly decreased hemolytic 
activity, thereby enhancing target selectivity. 
One of the synthesized lipo-γ-AApeptides 
did not induce drug resistance in methicil-
lin-resistant S. aureus, even after 17 passages 
(Niu et al., 2012).
LOOKING BACK, LOOKING AHEAD
Considering that AMPs, like cecropins and 
defensins, have been identified some three 
decades ago, the failure in transforming 
their potential into therapeutics against 
resistant microbial infections might be felt 
as scorchingly disappointing. However, 
great advances in our understanding of 
AMPs’ physicochemical properties and 
modes of action are fostering the develop-
ment of a new wave of peptidomimetics, 
inspired by naturally occurring examples, 
that could remove the hurdles that have 
prevented the adoption of AMPs in clinical 
settings. The next few years will be crucial in 
showing whether this view is correct.
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